Stereotactic radiosurgical capsulotomy may eventually help treat people with treatment-resistant major depressive disorder.

The FDA has cleared Motivista, the first prescription digital therapeutic indicated to treat negative symptoms of schizophrenia as an adjunct to antipsychotic therapy.

Most youths with opioid use disorder do not receive medications for OUD or engage in care, leading to a higher rate of overdose deaths.

Topline phase 3 ARISE trial results show oral solengepras 150mg significantly reduces OFF time and improves motor/non-motor function in Parkinson disease.

Dexmedetomidine administration is rising in opioid use disorder-related hospitalizations due to medetomidine appearing in illicit fentanyl.

Higher levels of exhaled carbon monoxide are linked to a decreased risk for Parkinson disease in adults without a history of smoking.

Laxative misuse and dietary restriction in bulimia nervosa are associated with specific structural brain changes including lower hippocampal volume.

A novel machine learning model accurately screened for psychologic distress in patients with chronic rhinosinusitis using routine clinical variables.

A brief psychosocial intervention for older adults initiating antidepressants improves illness perceptions compared with standard care.

High rates of concurrent anxiety and depressive disorders are observed among youths with opioid and cannabis use challenges.

Patients with HIV who had frequent outpatient psychiatric visits and poor viral control faced a significantly higher likelihood for hospital admission.

Patients with cancer and preexisting depression experience a significantly higher risk for cancer-specific mortality.